Subsequent Events - Ampreloxetine Funding (Details) $ in Thousands		3 Months Ended	6 Months Ended
	Jul. 20, 2022 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2022 USD ($)
Subsequent Event [Line Items]
Legal expenses		$ 3,778	$ 5,057
Ampreloxetine Royalty Rights | Subsequent Events
Subsequent Event [Line Items]
Consideration Receivable at closing	$ 25,000
Consideration received at the time of first approval	$ 15,000
Patent Application Period	5 years
Ampreloxetine Royalty Rights | Net Sales Upto First 500 Million | Subsequent Events
Subsequent Event [Line Items]
Consideration received	$ 500,000
Royalty Payment Percentage Multiplied with Net Sales	2.5
Ampreloxetine Royalty Rights | Net Sales In Excess of 500 Million | Subsequent Events
Subsequent Event [Line Items]
Consideration received	$ 500,000
Royalty Payment Percentage Multiplied with Net Sales	4.5